- Home
- STEC vs NRXP Comparison
STEC vs NRXP Comparison
Compare STEC & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- NRXP
- Stock Information
- Founded
- STEC 2006
- NRXP 2015
- Country
- STEC China
- NRXP United States
- Employees
- STEC N/A
- NRXP N/A
- Industry
- STEC
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- STEC
- NRXP Health Care
- Exchange
- STEC NYSE
- NRXP Nasdaq
- Market Cap
- STEC 29.7M
- NRXP 32.6M
- IPO Year
- STEC 2021
- NRXP N/A
- Fundamental
- Price
- STEC $0.97
- NRXP $3.29
- Analyst Decision
- STEC
- NRXP Strong Buy
- Analyst Count
- STEC 0
- NRXP 4
- Target Price
- STEC N/A
- NRXP $28.50
- AVG Volume (30 Days)
- STEC 12.1K
- NRXP 288.4K
- Earning Date
- STEC 07-01-2025
- NRXP 08-13-2025
- Dividend Yield
- STEC N/A
- NRXP N/A
- EPS Growth
- STEC N/A
- NRXP N/A
- EPS
- STEC N/A
- NRXP N/A
- Revenue
- STEC $28,023,000.00
- NRXP N/A
- Revenue This Year
- STEC $9,392.20
- NRXP N/A
- Revenue Next Year
- STEC N/A
- NRXP N/A
- P/E Ratio
- STEC N/A
- NRXP N/A
- Revenue Growth
- STEC 50.79
- NRXP N/A
- 52 Week Low
- STEC $0.20
- NRXP $1.10
- 52 Week High
- STEC $3.25
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- STEC 43.73
- NRXP 60.87
- Support Level
- STEC $0.97
- NRXP $3.14
- Resistance Level
- STEC $1.02
- NRXP $3.61
- Average True Range (ATR)
- STEC 0.08
- NRXP 0.26
- MACD
- STEC 0.00
- NRXP -0.02
- Stochastic Oscillator
- STEC 14.78
- NRXP 53.17
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.